Respiratory syncytial virus immune globulin intravenous: Indications for use

N. A. Halsey, J. S. Abramson, P. J. Chesney, M. C. Fisher, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, Dennis L Murray, G. D. Overturf, R. J. Whitley, R. Yogev, G. Peter, C. B. Hall, Jr Overall, R. Berkelman, W. A. Orenstein, R. Breiman, M. C. Hardegree, R. F. JacobsN. E. MacDonald, N. R. Rabinovich, W. Oh, L. R. Blackmon, A. A. Fanaroff, B. V. Kirkpatrick, H. M. MacDonald, C. A. Miller, A. Papile, C. T. Shoemaker, M. E. Speer, P. Johnson, Jr Greene, D. D. McMillan, D. Rowley, L. L. Wright, J. C. Langer

Research output: Contribution to journalReview articlepeer-review

81 Scopus citations


Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (≤35 weeks of gestation). RSV-IGIV administered monthly during the RSV season resulted in a 41% to 65% reduction in hospitalization rates in two clinical trials; however, RSV-IGIV is costly, and intravenous administration can be logistically demanding. RSV-IGIV should be considered for infants with bronchopulmonary dysplasia who are receiving or have received oxygen therapy in the past 6 months. Infants with gestational ages of 32 weeks or less may also benefit clinically from RSV-IGIV prophylaxis. Immunization with measles- containing vaccines should be delayed for 9 months after the last dose of RSV-IGIV, but no changes need to be made for all other routinely administered vaccines. RSV-IGIV has not been approved for use in children with congenital heart disease, and available data indicate that RSV-IGIV should not be administered to children with cyanotic congenital heart disease because of safety concerns.

Original languageEnglish (US)
Pages (from-to)645-650
Number of pages6
Issue number4
StatePublished - Apr 1997

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Respiratory syncytial virus immune globulin intravenous: Indications for use'. Together they form a unique fingerprint.

Cite this